- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01523171
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)
A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary Objective:
- To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), or post-essential thrombocythemia myelofibrosis (Post-ET MF) based on the reduction of spleen volume at the end of 6 treatment cycles;
Secondary Objectives:
- To evaluate the effect of SAR302503 on Myelofibrosis (MF) associated symptoms as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary
- To evaluate the durability of splenic response
- To evaluate the splenic response to SAR302503 by palpation at the end of Cycle 6
- To evaluate the splenic response to SAR302503 at the end of Cycle 3
- To evaluate the effect of SAR302503 on the Janus kinase 2 (JAK2) V617F allele burden
- To evaluate the safety and tolerability of SAR302503 in this population
- To evaluate plasma concentrations of SAR302503 for population PK analysis, if warranted
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Frankfurt Am Main, Allemagne, 60590
- Investigational Site Number 276003
-
Leipzig, Allemagne, 04103
- Investigational Site Number 276007
-
Magdeburg, Allemagne, 39120
- Investigational Site Number 276006
-
Mannheim, Allemagne, 68167
- Investigational Site Number 276001
-
Ulm, Allemagne, 89081
- Investigational Site Number 276005
-
-
-
-
-
Antwerpen, Belgique, 2060
- Investigational Site Number 056002
-
Leuven, Belgique, 3000
- Investigational Site Number 056003
-
-
-
-
-
Toronto, Canada, M5G 2M9
- Investigational Site Number 124001
-
-
-
-
-
Barcelona, Espagne, 08036
- Investigational Site Number 724001
-
Majadahonda, Espagne, 28222
- Investigational Site Number 724003
-
Salamanca, Espagne, 37007
- Investigational Site Number 724002
-
-
-
-
-
Marseille, France, 13273
- Investigational Site Number 250001
-
Nimes Cedex 9, France, 30029
- Investigational Site Number 250003
-
Paris Cedex 10, France, 75475
- Investigational Site Number 250002
-
Paris Cedex 12, France, 75571
- Investigational Site Number 250006
-
Toulouse, France, 31000
- Investigational Site Number 250004
-
-
-
-
-
Firenze, Italie, 50134
- Investigational Site Number 380004
-
Milano, Italie, 20122
- Investigational Site Number 380001
-
Roma, Italie, 00161
- Investigational Site Number 380002
-
Varese, Italie, 21100
- Investigational Site Number 380003
-
-
-
-
-
Salzburg, L'Autriche, 5020
- Investigational Site Number 040002
-
Wien, L'Autriche, 1090
- Investigational Site Number 040001
-
-
-
-
-
Amsterdam, Pays-Bas, 1081 HV
- Investigational Site Number 528002
-
Maastricht, Pays-Bas, 6229 HX
- Investigational Site Number 528003
-
Nijmegen, Pays-Bas, 6525 GA
- Investigational Site Number 528001
-
-
-
-
-
London, Royaume-Uni, SE1 9RT
- Investigational Site Number 826001
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Investigational Site Number 840007
-
-
California
-
San Francisco, California, États-Unis, 94143
- Investigational Site Number 840003
-
San Francisco, California, États-Unis, 94143
- Investigational Site Number 840004
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Investigational Site Number 840005
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Investigational Site Number 840014
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160-7321
- Investigational Site Number 840001
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Investigational Site Number 840017
-
Baltimore, Maryland, États-Unis, 21229
- Investigational Site Number 840013
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109-0759
- Investigational Site Number 840010
-
-
New York
-
New York, New York, États-Unis, 10021
- Investigational Site Number 840009
-
New York, New York, États-Unis, 10032
- Investigational Site Number 840018
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Investigational Site Number 840022
-
Middletown, Ohio, États-Unis, 45042
- Investigational Site Number 840019
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29406
- Investigational Site Number 840024
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Investigational Site Number 840002
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112-5550
- Investigational Site Number 840015
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion criteria:
- Diagnosis of PMF or Post-PV MF or Post-ET MF, according to the 2008 World Health Organization and IWG-MRT response criteria
- Subjects who previously received Ruxolitinib treatment for PMF or Post-PV MF or Post-ET MF or PV or ET for at least 14 days (exposure of <14 days is allowed for subjects who discontinued Ruxolitinib due to intolerability or allergy) and discontinued the treatment for at least 14 days prior to the first dose of SAR302503
- MF classified as Intermediate-1 with symptoms, Intermediate-2 or high-risk by Dynamic International Prognostic Scoring System (Passamonti et al., Blood 2010)
- Spleen ≥5 cm below costal margin as measured by palpation
- Male and female subjects ≥18 years of age
- Signed written informed consent
Exclusion criteria:
- Splenectomy
- Eastern Cooperative Oncology Group (ECOG) performance status of >2 before the first dose of SAR302503 at Cycle 1 Day1
The following laboratory values within 14 days prior to the initiation of SAR302503:
- Absolute Neutrophil Count (ANC) <1.0 x 10exp9/L
- Platelet count <50 x 10exp9/L
- Serum creatinine >1.5 x Upper limit of normal (ULN)
- Serum amylase and lipase >1.5 x ULN
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.5 x ULN
- Total bilirubin ≥3.0 x ULN
- Subjects with total bilirubin between 1.5-3.0 x ULN must be excluded if the direct bilirubin fraction is ≥25% of the total
- Subjects with known active (acute or chronic) Hepatitis A, B, or C; and Hepatitis B and C carriers
- Prior history of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH])
- Subjects with any other prior malignancies are not eligible, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which subject has been disease-free for at least 5 years
- Any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), Anagrelide, immunosuppressive therapy, corticosteroids >10 mg/day prednisone or equivalent, or growth factor treatment (eg, erythropoietin), or hormones (eg, androgens, danazol) within 14 days prior to initiation of SAR302503; darbepoetin use within 28 days prior to initiation of SAR302503.The only chemotherapy allowed will be hydroxyurea within 1 day prior to initiation of SAR302503
- Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of SAR302503
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: SAR302503 400 mg
once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
|
Forme pharmaceutique : gélule Voie d'administration : orale |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 6 as measured by Magnetic Resonance Imaging (MRI) (or CT scan in subjects with contraindications for MRI)
Délai: 6 months
|
6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score using the modified MFSAF
Délai: 6 months
|
6 months
|
Duration of spleen response, measured by MRI (or CT scan in subjects with contraindications for MRI)
Délai: 6 months
|
6 months
|
Proportion of subjects with a ≥50% reduction in length of spleen by palpation from baseline at the end of Cycle 6
Délai: 6 months
|
6 months
|
Response Rate at the end of Cycle 3, defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 3 as measured by MRI (or CT scan in subjects with contraindications for MRI)
Délai: 6 months
|
6 months
|
Percent change of spleen volume at the end of Cycles 3 and 6 from baseline as measured by MRI (or CT scan in subjects with contraindications for MRI)
Délai: 6 months
|
6 months
|
Safety, as assessed by clinical, laboratory, ECG, and vital sign events; graded by the NCI CTCAE v4.03
Délai: approximately 5 years
|
approximately 5 years
|
Plasma concentrations of SAR302503
Délai: 4 months
|
4 months
|
The effect of SAR302503 on the JAK2V617F allele burden
Délai: 2 years
|
2 years
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ARD12181
- 2011-005226-21 (Numéro EudraCT)
- U1111-1124-0967 (Autre identifiant: UTN)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur SAR302503
-
SanofiComplétéNéoplasme hématopoïétiqueÉtats-Unis
-
SanofiComplétéNéoplasme hématopoïétiqueL'Autriche, Allemagne, Italie, Espagne, Royaume-Uni, France, Belgique, Israël, Suède, Australie, États-Unis, Lituanie, Le Portugal, Corée, République de, Singapour, Taïwan, Mexique, Brésil, Canada, Hongrie, Irlande, Pologne, Roumanie, Fédération... et plus
-
SanofiComplétéInsuffisance rénaleÉtats-Unis
-
SanofiComplétéInsuffisance hépatiqueÉtats-Unis
-
SanofiComplété
-
SanofiComplétéTumeur maligneBelgique, États-Unis
-
SanofiComplétéNéoplasme hématopoïétiqueÉtats-Unis, Espagne, France, Canada, Australie, Corée, République de, Allemagne, Italie, Royaume-Uni
-
University of WashingtonRecrutementLeucémie myéloïde aiguë | Myélofibrose primaire | Polyglobulie Vera | Thrombocytémie essentielle | Syndrome myélodysplasique | Tumeur myéloproliférative | Tumeur myélodysplasique/myéloproliférative | Myélofibrose secondaire | Tumeur myéloproliférative inclassableÉtats-Unis
-
SanofiComplétéTumeur solideÉtats-Unis